Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Complete phenotypic recovery of an Alzheimer's disease model by a quinone-tryptophan hybrid aggregation inhibitor.

PloS one - 14 Jun 2010

Scherzer-Attali Roni, Pellarin Riccardo, Convertino Marino, Frydman-Marom Anat, Egoz-Matia Nirit, Peled Sivan, Levy-Sakin Michal, Shalev Deborah E, Caflisch Amedeo, Gazit Ehud, Segal Daniel

Abstract excerpt

The rational design of amyloid oligomer inhibitors is yet an unmet drug development need. Previous studies have identified the role of tryptophan in amyloid recognition, association and inhibition. Furthermore, tryptophan was ranked as the residue with highest amyloidogenic propensity. Other studies have demonstrated that quinones, specifically anthraquinones, can serve as aggregation inhibitors probably due to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer Disease
Share to Circular Dichroism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Magnetic Resonance Spectroscopy

Share to Models, Biological

Share to Models, Molecular

Share to Naphthoquinones

Share to Quinones

Share to Tryptophan

Source

Open in PubMed Open full text

Identifiers

PMID: 20559435
DOI: 10.1371/journal.pone.0011101
PMCID: PMC2885425

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Complete phenotypic recovery of an Alzheimer's disease model by a quinone-tryptophan hybrid aggregation inhibitor.PMID 20559435Read ↗

Cl-NQTrp Alleviates Tauopathy Symptoms in a Model Organism through the Inhibition of Tau Aggregation-Engendered ToxicitySemantic proximity Read ↗

Combined Experimental and Simulation Studies Suggest a Revised Mode of Action of the Anti‐Alzheimer Disease Drug NQ‐TrpSemantic proximity Read ↗

Targeting Amyloid Aggregation: An Overview of Strategies and MechanismsSemantic proximity Read ↗

The Flavonoid Derivative 2-(4′ Benzyloxyphenyl)-3-hydroxy-chromen-4-one Protects Against Aβ42-Induced Neurodegeneration in Transgenic Drosophila: Insights from In Silico and In Vivo StudiesSemantic proximity Read ↗

Potential Azo-8-hydroxyquinoline derivatives as multi-target lead candidates for Alzheimer’s disease: An in-depth in silico study of monoamine oxidase and cholinesterase inhibitorsSemantic proximity Read ↗

De novo designed protein inhibitors of amyloid aggregation and seedingSemantic proximity Read ↗

Mitigating protein aggregation to reduce the toxicity inherent to Parkinson's and Alzheimer's diseasesSemantic proximity Read ↗

Hybrids of oxoisoaporphine–tetrahydroisoquinoline: novel multi-target inhibitors of inflammation and amyloid-β aggregation in Alzheimer’s diseaseSemantic proximity Read ↗

Identification of structural features of selected flavonoids responsible for neuroprotection using a <i>Drosophila</i> model of Parkinson’s diseaseSemantic proximity Read ↗

Systematic In Vivo Analysis of the Intrinsic Determinants of Amyloid β PathogenicitySemantic proximity Read ↗

Designed inhibitors to reduce amyloid virulence and cytotoxicity and combat neurodegenerative and infectious diseasesSemantic proximity Read ↗

Thiadiazolidinone (TDZD) Analogs Inhibit Aggregation-Mediated Pathology in Diverse Neurodegeneration Models, and Extend C. elegans Life- and HealthspanSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.